In 2005, the American Academy of Neurology and the Child Neurology Society published a practice parameter, based primarily on studies that involved 6 to 18 months of treatment, indicating that prednisone has a beneficial effect on muscle strength and function in patients with Duchenne muscular dystrophy and recommended that corticosteroids be offered (prednisone 0.75 mg/kg/d and deflazacort 0.9 mg/kg/d) as treatment. Recent reports emphasize that longer term treatment with corticosteroids (greater than 3 years) produces important sustained benefits in neuromuscular function without causing major side effects. This review highlights these reports and indicates that long-term corticosteroid therapy (1) prolongs ambulation by 2 to 5 years, (2) reduces the need for spinal stabilization surgery, (3) improves cardiopulmonary function, (4) delays the need for noninvasive nasal ventilation, and (5) increases survival and the quality of life of patients with Duchenne muscular dystrophy. Educational, vocational, and other social counseling is now a vital part of management for Duchenne muscular dystrophy.
Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years-four states, 2007. MMWR Morb Mortal Wkly Rep . 2009;58(40):1119-1122.
2.
Hoffmann E.Dystrophinopathies. In: Karpati G, Hilton-Jones D, Griggs R , eds. Disorders of Voluntary Muscle. Cambridge, UK: Cambridge University Press; 2001:385-432.
3.
Moxley RT III.Clinical overview of Duchenne Muscular Dystrophy. In: Chamberlain J, Rando T, eds. Duchenne Muscular Dystrophy: Advances in Therapeutics. New York, NY: Taylor & Francis Group;2006:1-20.
4.
Brooke MH, Fenichel GM, Griggs RC, et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology. 1989;39(4):475-481.
5.
Bushby K., Finkel R., Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol.2010;9(1):77-93.
6.
Bushby K., Finkel R., Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol.2010;9(2):177-189.
7.
Eagle M., Baudouin SV, Chandler C., Giddings DR, Bullock R., Bushby K.Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002; 12(10):926-929.
8.
Eagle M., Bourke J., Bullock R., et al. Managing Duchenne muscular dystrophy-the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord. 2007;17(6):470-475.
Rahbek J., Werge B., Madsen A., Marquardt J., Steffensen BF, Jeppesen J.Adult life with Duchenne muscular dystrophy: observations among an emerging and unforeseen patient population. Pediatr Rehabil. 2005;8(1):17-28.
11.
Ciafaloni E. , Fox DJ, Pandya S., et al. Delayed diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr.2009;155(3):380-385.
12.
Moxley RT III , Ashwal S., Pandya S., et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005;64(1):13-20.
13.
Manzur AY, Kuntzer T., Pike M., Swan A.Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2008;(1):CD003725.
14.
Drachman DB , Toyka KV, Myer E.Prednisone in Duchenne muscular dystrophy . Lancet. 1974;2(7894):1409-1412.
15.
Siegel IM, Miller JE, Ray RDFailure of corticosteroid in the treatment of Duchenne (pseudo-hypertrophic) muscular dystrophy: report of a clinically matched three year double-blind study. IMJ Ill Med J. 1974;145(1):32-33.
16.
DeSilva S., Drachman DB, Mellits D., Kuncl RWPrednisone treatment in Duchenne muscular dystrophy: long-term benefit. Arch Neurol. 1987;44(8):818-822.
17.
Brooke MH, Fenichel GM, Griggs RC, et al. Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone. Arch Neurol. 1987;44(8):812-817.
18.
Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne’s muscular dystrophy. N Engl J Med. 1989;320(24):1592-1597.
19.
Fenichel GM, Mendell JR, Moxley RT III, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol . 1991;48(6):575-579.
20.
Fenichel GM, Florence JM, Pestronk A., et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology. 1991;41(12):1874-1877.
21.
Griggs RC, Moxley RT III, Mendell JR, et al. Prednisone in Duchene dystrophy: a randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol. 1991;48(4):383-388.
22.
Balaban B., Matthews DJ, Clayton GH, Carry T.Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil. 2005 ; 84(11):843-850.
23.
Biggar WD, Harris VA, Eliasoph L., Alman B.Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006;16(4): 249-255.
24.
Houde S., Filiatrault M., Fournier A., et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up . Pediatr Neurol. 2008;38(3):200-206.
25.
King WM, Ruttencutter R., Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007;68(19):1607-1613.
26.
Markham LW, Kinnett K., Wong BL, Woodrow BD, Cripe LHCorticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord. 2008;18(5):365-370.
27.
Miller LA, Romitti PA, Cunniff C., et al. The muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology. Birth Defects Res A Clin Mol Teratol. 2006;76(11):793-797.
28.
Rideau Y., Jankowski LW, Grellet J.Respiratory function in the muscular dystrophies. Muscle Nerve . 1981;4(2):155-164.
29.
Meaney F., Pandya S., Andrews J., Davis M.Palliative care services in families of males with Duchenne muscular dystrophy . Neuromuscul Disord. 2007;17(9):866.
